» Articles » PMID: 6636048

Heparin Inactivation During Blood Storage: Its Prevention by Blood Collection in Citric Acid, Theophylline, Adenosine, Dipyridamole-C.T.A.D. Mixture

Overview
Journal Thromb Res
Date 1983 Jul 15
PMID 6636048
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

An attempt was made to prevent heparin inactivation during the time that lapses between blood collection and laboratory assay. The blood collection in a combination of citric acid, theophylline, adenosine, dipyridamole - C.T.A.D. mixture - was found to reduce greatly the heparin loss during blood centrifugation and storage whatever the temperature for these two steps (centrifugation at 4 degrees C, 12 degrees C or 25 degrees C; storage at 4 degrees C or 20-25 degrees C). With this mixture the influence of centrifugation temperature upon the heparin loss appeared negligible. The heparin loss during the initial 5 hours storage at 20 degrees-25 degrees C was found to be 4.4 +/- 4% for a heparin concentration of 0.45 +/- 0.05IU/ml. The combination of the platelet active drugs with citric acid in C.T.A.D. mixture did not interfere either with the amidolytic heparin assay (anti IIa) or clotting tests such as activated partial thromboplastin time and calcium thrombin time. Thus the C.T.A.D. mixture appears to be useful in routine use because it is effective, cheap, stable, does not interfere with the tests currently used for monitoring heparin therapy and thus helps overcome the main cause of error in heparin assays.

Citing Articles

Management of Therapeutic-intensity Unfractionated Heparin: A Narrative Review on Critical Points.

Gouin-Thibault I, Mansour A, Hardy M, Gueret P, De Maistre E, Siguret V TH Open. 2024; 8(3):e297-e307.

PMID: 39420916 PMC: 11486528. DOI: 10.1055/a-2359-0987.


Monitoring heparin therapy: stability of two different anti-Xa assays using blood samples collected in citrate-containing and CTAD tubes.

Gremillet M, Talon L, Lebreton A, Sinegre T Thromb J. 2023; 21(1):21.

PMID: 36803983 PMC: 9942401. DOI: 10.1186/s12959-023-00465-8.


Effects of Primary Mast Cell Disease on Hemostasis and Erythropoiesis.

Seidel H, Hertfelder H, Oldenburg J, Kruppenbacher J, Afrin L, Molderings G Int J Mol Sci. 2021; 22(16).

PMID: 34445665 PMC: 8396658. DOI: 10.3390/ijms22168960.


Optimization of Heparin Monitoring with Anti-FXa Assays and the Impact of Dextran Sulfate for Measuring All Drug Activity.

Amiral J, Amiral C, Dunois C Biomedicines. 2021; 9(6).

PMID: 34205548 PMC: 8235539. DOI: 10.3390/biomedicines9060700.


Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays.

Douxfils J, Tamigniau A, Chatelain B, Goffinet C, Dogne J, Mullier F Thromb J. 2015; 12:24.

PMID: 25750588 PMC: 4351835. DOI: 10.1186/1477-9560-12-24.